Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OA-SYS in moderate to severe knee osteoarthritis
NCT06485843Phase 2Recruiting
- Sponsor
- Ageless Biotech
- Start
- May 2025
- Primary completion
- Mar 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OA-SYS in osteoarthritis (OA), sponsored by Ageless Biotech. Primary endpoint: Adverse Events at 52 weeks. Started May 2025; status: recruiting.
02
Drugs
OA-SYS
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06485843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485843.